Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
National Institutes of Health (NIH)
Funding duration: UG3 phase up to 2 years, UH3 phase up to 5 years
Total funding amount: Not specified
To encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER)
Research must align with the mission and interests of NINDS
Investigators in clinical neuroscience
Patients and healthcare providers
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, small businesses, local, state, and federal governments, and foreign organizations.
Specific qualifications include having the necessary skills, knowledge, and resources to carry out the proposed research.
Eligible organizations can be based in the U.S. or be foreign organizations.
Non-domestic components of U.S. organizations are also eligible.
Projects must focus on prospective observational studies.
Studies should address health disparities and under-researched conditions.
Application budgets are not limited but must reflect the actual needs of the proposed project.
Cost sharing is not required.
Application due date: September 7, 2025
Open date for applications: January 19, 2025
Applicants may submit more than one application, provided each is scientifically distinct.
The NIH will not accept duplicate or overlapping applications.
Applications must follow the instructions in the Research Application Guide.
A letter of intent is encouraged but not required.
Applications will be evaluated based on scientific and technical merit.
Review criteria include significance, innovation, rigor, and feasibility.
Applications will undergo peer review and may receive a second level of review by the national Advisory Council or Board.
Priority will be given to projects that address health disparities and have high potential impact.
The UG3/UH3 application must be submitted as a single application.
Only UG3 projects that meet milestones may transition to the UH3 phase.
Transition to the UH3 phase is contingent on meeting specific milestones and program priorities.
Encouragement to establish relationships with patient groups for input on study design.
Strong emphasis on pragmatic study designs may provide a competitive edge.
Meeting scientific milestones during the UG3 phase is crucial for transitioning to UH3.
Submitting overlapping applications or failing to adhere to application guidelines.
Engage with NINDS staff early in the application process for guidance.
Focus on addressing health disparities and under-researched conditions to enhance competitiveness.